Core Viewpoint - HPQ Silicon Inc. has successfully completed a non-brokered private placement, raising approximately $3 million CAD through the issuance of 18,181,819 units at a price of $0.165 CAD per unit, indicating strong institutional investor support [1][2]. Group 1: Offering Details - The private placement consists of units, each comprising one common share and one non-transferable common share purchase warrant, with warrants exercisable at $0.25 CAD for 24 months post-closing [3]. - The offering is expected to close around February 27, 2026, pending necessary approvals from the TSX Venture Exchange [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for general working capital, accelerating the execution of the Silicon-Based Battery Material pilot plant project, and continuing the development of hydrogen-based projects [4]. Group 3: Company Overview - HPQ Silicon Inc. is focused on advanced materials technology, particularly in the production of high-purity silicon and silica for energy storage and industrial applications [1][5]. - The company is collaborating with Novacium to develop next-generation silicon-based anode materials and is also working on clean-hydrogen and waste-to-energy technologies [5][6]. - HPQ aims to become a low-cost, zero-CO₂ producer of fumed silica and high-purity silicon, positioning itself to capture growth opportunities in energy storage and clean hydrogen markets [6].

Core Insights - The FDA has approved Dupixent (dupilumab) as the first and only treatment for allergic fungal rhinosinusitis (AFRS) in patients aged 6 years and older with a history of sino-nasal surgery, marking a significant advancement in the treatment of this condition [2][3][4] Group 1: Approval and Indications - Dupixent is now approved for treating nine distinct diseases driven by type 2 inflammation, including sino-nasal, skin, gut, and respiratory system diseases [6] - The approval was based on the LIBERTY-AFRS-AIMS phase 3 study, which demonstrated significant improvements in sinus opacification scores and nasal symptoms compared to placebo [4][10] Group 2: Clinical Study Results - In the LIBERTY-AFRS-AIMS study, Dupixent improved sinus opacification scores by 50% compared to 10% for placebo at Week 52, with a significant reduction also observed at Week 24 [4][11] - Patient-reported nasal congestion improved by 67% at Week 24 and 81% at Week 52 compared to 25% and 11% for placebo, respectively [7][13] - Dupixent reduced the risk of systemic corticosteroid use and/or surgery by 92%, with only 3% of patients on Dupixent requiring systemic corticosteroids compared to 31% on placebo [13] Group 3: Safety Profile - The safety profile of Dupixent in the LIBERTY-AFRS-AIMS study was consistent with its known safety profile in chronic rhinosinusitis with nasal polyps (CRSwNP), with common adverse reactions including injection site reactions and conjunctivitis [8][9] Group 4: Market Impact and Future Plans - Dupixent's approval is expected to establish a new standard of care for patients with AFRS, addressing a high unmet need in the treatment landscape [9] - Sanofi and Regeneron plan to submit additional applications to regulatory authorities worldwide to expand access to Dupixent [9][17]

Core Insights - Davis Commodities Limited has enhanced its position as a global agri-commodities platform, securing approximately US$20 million in orders and advanced discussions following a successful international food trade exhibition [1][12] - The company has generated around US$100 million in revenue from repeat customer transactions, indicating strong trade relationships and a growing preference for its services in key markets [2][3] Revenue Growth and Stability - The recurring demand from customers reflects trust in the company's execution capabilities and pricing discipline, which is crucial for earnings quality and financial stability [3] - The US$100 million in recurring revenue is increasingly driven by higher value-added products under the Maxwill brand, supporting a more resilient earnings profile over time [3][10] Strategic Partnerships - Davis Commodities has secured supply arrangements with leading FMCG manufacturers in Singapore, enhancing its customer portfolio and market credibility [5][6] - These partnerships are expected to contribute significantly to revenue continuity and strengthen the company's position as a preferred supply partner for high-volume procurement [6][7] Market Expansion and Financial Performance - The US$20 million pipeline from the exhibition demonstrates the company's ability to convert international market access into financial outcomes, primarily for essential food commodities [8][10] - The combination of new deals and repeat transactions creates a dual-engine growth model, positioning the company to benefit from resilient global demand [10][11] Management Strategy and Outlook - The management emphasizes disciplined execution, focusing on deepening partnerships, expanding into new markets, and growing the branded product portfolio [12][13] - The strong commercial outcomes and recurring revenue base provide a solid foundation for accelerated revenue recognition and improved earnings consistency [13][17] Operational Efficiency - The relationship-driven growth model reduces customer acquisition costs and improves working capital efficiency, enhancing operating cash flow generation [9][15] - The company aims to build a diversified, higher-margin earnings structure while maintaining transparent communication with capital markets [14][16]

U.S. Aluminum Company is new venture founded by Oklahoma City-based Plotkin Family, owners of leading aluminum fabrication company M-D Building ProductsINOLA, Okla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Local firm U.S. Aluminum Company has signed an agreement with EGA and Century Aluminum, the companies behind the planned primary aluminum production plant in Inola, Oklahoma, to explore the development of an aluminum fabrication plant near the new smelter. Click here to download photos of leaders from the three ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven in part by type 2 inflammation, i ...

U.S. spot ETF expands regulated access to the Sui ecosystem as institutional momentum acceleratesNEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- 21shares, one of the world’s leading issuers of crypto exchange-traded funds (ETFs), today announced the launch of the 21shares Spot SUI ETF (TSUI), which has officially started trading on Nasdaq. TSUI allows U.S. investors to integrate SUI into their portfolios via traditional brokerage accounts, without the need to directly hold or manage digital wallets. TSUI is not ...

Core Viewpoint - WisdomTree Multi Asset Issuer Public Limited Company has successfully passed an Extraordinary Resolution to reduce the principal amount of the WisdomTree S&P 500 VIX Short-Term Futures 2.25x Daily Leveraged Securities from USD 0.481 to USD 0.0481, indicating a significant adjustment in the value of the affected securities [2]. Group 1 - The Extraordinary Resolution was passed at an adjourned meeting held on 24 February 2026 [2]. - The reduction in principal amount reflects a change in the financial structure of the affected securities [2]. - A Deed of Amendment has been executed to implement the proposed amendments to the Trust Deed effective from 24 February 2026 [3].

Core Viewpoint - Clean Energy Technologies, Inc. (CETY) is updating its investment in a convertible bond issued by China Ruifeng Renewable Energy Holdings Limited, which is planning a significant investment in an artificial intelligence computing center project in China [1][2][3]. Investment Update - CETY has entered into a purchase agreement to acquire a portion of a convertible bond from China Ruifeng [2]. - China Ruifeng announced plans for a potential investment of approximately US$ 3.4 billion through its subsidiary Leading Win Resources Limited to develop a large-scale artificial intelligence computing center in Xuanhua District, Hebei Province, China [3]. Project Details - The project aims to develop an artificial intelligence computing center integrated with renewable power supply and energy storage infrastructure, targeting high-density computing workloads [4]. - Initial operations for the project are expected to launch in 2028, and it may include a grid-side energy storage facility utilizing lithium iron phosphate technology [4]. Company Positioning - CETY is not a party to the investment framework agreement and has not entered into any definitive agreements with China Ruifeng regarding the project [5]. - The company notes that such projects typically require advanced energy infrastructure solutions, aligning with CETY's technology focus and strategic objectives [5]. - CETY's experience in energy infrastructure development positions it to evaluate potential collaborations with Leading Win Resources Limited or its affiliates [5].

VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Forte Minerals Corp. (“Forte” or the “Company”) (CSE: CUAU) (OTCQB: FOMNF) (Frankfurt: 2OA) a Canadian copper and gold exploration company focused on Peru, is pleased to announce that it will exhibit at the Prospectors & Developers Association of Canada (“PDAC”) Convention 2026, taking place March 1–4, 2026 at the Metro Toronto Convention Centre in Toronto. Visit Forte Minerals Corp at Booth 2736 in the Investors Exchange (South Building). PDAC ...

BROSSARD, Quebec, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical eye-related health issues using advanced technology based on Artificial Intelligence (AI), is pleased to announce that it will be presenting at the Centurion One Capital 9th Annual Conference in Toronto, Canada March 5th 2026. This exclusive gathering unites the most significant group of Canadian investors in sea ...